fbpx COVID-19 (Coronavirus): ADB's Response | Asian Development Bank

COVID-19 (Coronavirus): ADB's Response

ADB is supporting its developing members in responding to the COVID-19 outbreak through finance, knowledge, and partnerships.

In the Spotlight

Publication | 07 May 2021

One Year of Living with COVID-19: An Assessment of How ADB Members Fought the Pandemic in 2020

Using the ADB COVID-19 Policy Database, this report examines how ADB members have dealt with the pandemic. It includes information on the amounts of the packages announced by ADB members during 2020 to combat the effects of COVID-19.

News Release | 22 Jun 2021

ADB Approves $940 Million for Bangladesh COVID-19 Vaccines

The Asian Development Bank has approved a loan package of $940 million for the Government of Bangladesh to purchase safe and effective vaccines against the coronavirus disease (COVID-19).

Article

Countering vaccine hesitancy: Lessons from India, Indonesia, and the Philippines

Misinformation was a serious issue in COVID 19 vaccination rollouts. Here’s how India, Indonesia, and the Philippines addressed the issue.

News Release

$9 Billion ADB Facility to Help Developing Member Countries Access and Distribute COVID-19 Vaccines

ADB has launched a $9 billion vaccine initiative—the Asia Pacific Vaccine Access Facility (APVAX)—offering rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.

ADB’s COVID-19 response consists of a $20 billion package announced in April 2020 and the $9 billion Asia Pacific Vaccine Access Facility (APVAX) announced in December 2020.

ADB’s initial $20 billion COVID-19 response package supports its developing member countries in countering the severe macroeconomic and health impacts caused by COVID-19, including $2.5 billion in concessional and grant resources, as well as $2 billion earmarked for the private sector (non-sovereign).

ADB's $9 billion APVAX vaccine initiative offers rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.

Committed Amount is the financing approved by ADB's Board of Directors or Management for which the legal agreement has been signed by the borrower, recipient, or the investee company and ADB.
*Projects may be listed in more than one country or subregion. The number of projects excludes short-term finance transactions under the Trade Finance, Supply Chain Finance, and Microfinance Programs.

News and Multimedia   Subscribe to our newsletter

Publications and Documents


Milestones

Made with Flourish